Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGI

Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3stejSA
via IFTTT